It’s been a busy and exciting year at Quantum Surgical. Here are some of our highlights:

• The Paoli-Calmettes Institute in Marseille, France, acquired Epione. About 30 patients have since been treated by Dr Piana and his team.
• Quantum Surgical received €30 million financing from the European Investment Bank.
• Quantum Surgical launched the Epibone clinical study to assess Epione^®’s performance to treat bone tumors.
• Rush University System for Health in Chicago (IL) acquired Epione^®.
• Dr. Naranayan and his team celebrated the 150th patient treated at Baptist Health, Miami (FL).
• Quantum Surgical received the French National Institute of Industrial Property Award in the Start-up category.
• Quantum Surgical organized a webinar with the Baptist Health IO team.
• Quantum Surgical’s first symposiums took place in USA at Spectrum in Miami and in Europe at ECIO in Mallorca, Spain.
• Quantum Surgical obtained ISO 27001:2023 certification which attests to the security and rigor of its data management system.
• Bertin Nahum, CEO and co-founder, spoke at CES in Las Vegas, the biggest tech event in the world.
• Lucien Blondel, our CTO and co-founder, received the Surgical Robotics Industry Award of Industry Leadership.
• LSI Europe invited Quantum Surgical to present the Epione^® solution in Lisbon, Portugal.
• Quantum Surgical and Epione^® attended various events worldwide: Spectrum in Miami, FL; ECIO in Mallorca, Spain; CIRSE in Lisbon, Portugal; Medpeers in Amsterdam, The Netherlands…
• And 720+ patients have been treated overall!

We are really happy with everything we have achieved together as a team and with our partners, we look forward to 2025!

‍

A groundbreaking achievement: Miami Cardiac and Vascular Institute and Miami Cancer Institute, part of Baptist Health South Florida, led the nation as the first to offer Epione, a cutting-edge robotic-assisted technology for minimally invasive ablation procedures. This technology has successfully transformed care for countless cancer patients.

For patients like Jose, the battle against renal cell carcinoma is a marathon, not a sprint. Diagnosed in 2006, Jose underwent a complete nephrectomy, removing his entire left kidney. Last year, his journey took another challenging turn when he developed metastatic lesions in the lower lobe of his right lung and pancreas, requiring additional surgeries. But when a lesion appeared in his remaining kidney, surgery was no longer an option.

Facing this new hurdle, Jose’s team at Miami Cancer Institute turned to innovation. They recommended a minimally invasive procedure using Epione, a robotic-assisted technology for percutaneous ablation. Given the tumor type and its location, the team decided that cryoablation would provide Jose with the best possible outcome.

Dr. Ripal Gandhi, a vascular and interventional radiologist with over 15 years of experience, led Jose’s procedure. A global thought leader in minimally invasive therapies, Dr. Gandhi specializes in cutting-edge treatments for cancer, peripheral vascular disease, and more. His expertise and Epione’s advanced technology offered Jose a new path forward in his ongoing fight against cancer.

“The benefits of the Epione robotic system is it allows us to treat patients more precisely, we are able to access lesions which sometimes would take us hours or sometimes we could not treat at all,” shared Dr. Gandhi. “It allows us to treat patients who may have a lot of issues, who might have a lot of comorbidities, who might not be safely placed under anesthesia for a long period of time, where you can treat the patient much faster and do it safely.”

For Dr. Gandhi and his colleagues at Miami Cancer Institute, Epione has been a ‘game-changing technology’.

“When we are doing procedures robotically versus freehand, these procedures are done much faster. It’s really beneficial for everybody; it’s beneficial for the patient as they are under anesthesia for a shorter period of time, and we are able to do more procedures in the room. Patients can have a faster recovery,” adds Dr. Gandhi.

Thanks to this minimally invasive, cutting-edge procedure, Jose has been given a renewed sense of hope and a cancer-free future. He and his family are deeply grateful to Dr. Gandhi and the team at Miami Cancer Institute for their exceptional care. At his most recent follow-up appointment, Jose was thrilled to share that he remains cancer-free, a testament to the power of innovation and expertise in modern medicine.

Montpellier, September 7^th 2023 – French medical robotics company Quantum Surgical has obtained CE mark approval for the expanded use of its robotic platform, Epione®, in the treatment of lung tumors. With over 2 million new cases worldwide in 2020, including approximately500,000 in Europe, lung cancer is the leading cause of cance- related mortality[1]. This new feature will be presented with related clinical study results at the CIRSE 2023 conference in Copenhagen from September 9th to 13th by Dr. Bonnet, interventional radiologist at Gustave Roussy.

Quantum Surgical’s flagship product, the Epione® robotic platform, is dedicated to the curative treatment of cancers. Epione® allow sphysicians to treat inoperable tumors that are particularly difficult to reach,due to their size or their location, at an early stage, in a simple and effective way.  

Epione® can be used to treat abdominal tumors (including theliver, kidneys, and pancreas) and over 200 patients have already been treated inFrance and the United States.

The CE mark approval for lung tumors will expand thisinnovative, targeted, and minimally invasive treatment to new patients inEurope.

It is based on a clinical study conducted at Gustave Roussy, the leading cancer center in Europe (third worldwide), the results of which will be presented during the international scientific conference organized by CIRSE(Cardiovascular and Interventional Radiological Society of Europe).

"With Epione®, our goal is to provide patients with an effective, better targeted and minimally invasive treatment. While over 2 million new cases of lung cancer diagnosed each year worldwide, we are delighted that our technology can now be accessible to new patients in Europe" said Bertin Nahum, President and Co-founder of Quantum Surgical.

“Patients were treated at Gustave Roussy with thermal destruction of lung metastases as part of a clinical study investigating the feasibility and safety of robotic guidance. In this ongoing study, the Epione® robot has consistently enabled technical success and has proven to be safe. The Epione® robot could enhance the minimally nvasive management of small and hard-to-reach lung tumors," stated Professor Thierry De Baère, Interventional Radiologist in the Department of Therapeutic Imaging at Gustave Roussy and member of the scientific advisory board of Quantum Surgical.

Laetitia Messner, Chief Clinical Officer of Quantum Surgical, explains, "Coordinated by Professor De Baère, the clinical study has demonstrated the clinical performance and safety of Epione® in the treatment of lung tumors. The CE mark approval proves the relevance and effectiveness of Epione®, which will enable us to offer innovative, targeted, and less invasive treatments to new patients."

Epione® is a robotic-assisted percutaneous ablation system, using a robotic arm, a navigation system and a camera. This procedure is an alternative to surgery in which a needle is inserted through the skin to the tumor to destroy it. This technique makes it possible to treat tumors that are particularly difficult to reach, due to their size or theirl ocation.

Relying on the know-how of the practitioner,Epione® integrates all the steps of a percutaneous ablation procedure in asingle platform: planning, targeting, ablation, confirmation.

[1] Globocan 2020

‍

Montpellier, June 13, 2023 – A 50th patient has been treated using the Epione® robot from Quantum Surgical by the team of Pr. Laurent Milot, Deputy Chief Vascular & Interventional Radiology at the Hospices Civils de Lyon (France), highlighting a successful collaboration only 8 months post-acquisition.

Installed in November 2022, the team of the Hospices Civils de Lyon (HCL, France) are convinced of the value of this innovative platform from Quantum Surgical and celebrating that 50 patients have benefited from Epione®.Epione® can be used to treat early-stage abdominal tumors that are inoperable or particularly difficult to reach, due to their size or location.

HCL is the second hospital in the world offering this revolutionary platform to their patients. The first Epione® robot was acquired by the Institut Gustave Roussy (France) in January 2022 where the team has already treated more than 100 patients. The very first patient in the United States was also successfully treated using the Epione® robot at Baptist Hospital in Miami (Florida) last month.

Beyond the new procedural advantages it provides, Epione® makes it possible to offer patients a minimally invasive treatment. It improves their comfort and facilitates their recovery, due to the absence of surgery.

For physicians and hospitals, Epione® combines advanced robotic assistance with image-guided navigation and ablation confirmation tools to promote the standardization of minimally invasive tumor ablation procedures. This is a major challenge given that more than 4 million abdominal cancers are diagnosed each year in the world[1].

“I am very pleased with this milestone, which above all underlines the perfect match between the HCL teams and the Epione® robot, which delivers all its promises. We are very excited to continue to explore the many benefits of Epione® and to support the next steps in the development of robotics in interventional radiology. This will undoubtedly lead to significant progress and extend hope for patients we do not have treatment solutions for so far” explains Prof. Laurent Milot, Deputy Chief Vascular & Interventional Radiology.

“The implementation of the Epione® robot within the Hospices Civils de Lyon is a success: in eight months, 50 patients have already benefited from our technology, as part of their cancer treatment. Pr. LaurentMilot's teams are particularly enthusiastic. We are delighted with this collaboration, which improves access to care and patient comfort” said Bertin Nahum, president and co-founder of Quantum Surgical.

[1] Source: GlobalCancer Observatory

Montpellier, May 24, 2023 – Dr. Govindarajan Narayanan, chief of interventional oncology at Miami Cancer Institute and a vascular interventional radiologist with Miami Cardiac & Vascular Institute, successfully treated the first patient in the US with a liver tumor using Quantum Surgical’s Epione® robot. The procedure took place at Baptist Health South Florida in Miami, Florida, a few days after the Food and Drug Administration cleared Epione® robot for treatment of all abdominal cancers.

Quantum Surgical’s flagship product, the Epione® robotic platform, is dedicated to the curative treatment of cancers. Epione® allows physicians to treat inoperable tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.  

More than 150 patients have already been treated with the Epione® robot in Europe, and Dr. Narayanan successfully treated the first patient in the US.

“I am honored to be the first physician to utilize Epione® in the United States as this robotic-assisted equipment is going to change the way we deliver effective treatments to our patients for cancerous tumors,” said Dr. Narayanan. “Baptist Health has always been at the forefront when it comes to providing the very best care to the South Florida community and beyond. I am proud to be a part of such an incredible team.”

"We are very proud of this first intervention with our Epione® robot in the US! We are delighted to have been able to work with Dr. Narayanan and Baptist Health South Florida, renowned experts. This first intervention coincides with the FDA extension clearance to deploy our robotic solution in the United States. Dr. Narayanan is paving the way for physicians who will be able to offer more patients to benefit from innovative and less invasive treatments, and improve their lives" declares Bertin Nahum, President and co-founder of Quantum Surgical.

Epione® is a robot-assisted technology designed to plan, target, perform and confirm tumor ablation. Epione® enables physicians to perform percutaneous tumor ablations, a minimally invasive treatment in which one or more needles are inserted through the skin into the tumor to destroy it.

Epione® is currently available in Europe and the United States for treatment of all abdominal cancers. More than 4 million abdominal cancers occur each year worldwide[1].

[1] Source: Global Cancer Observatory

‍

Montpellier, May 3rd, 2023 - Quantum Surgical, a French medical robotics company, has received an extension of authorization from the US Food and Drug Administration (FDA) for its Epione® robot, which can now treat abdominal cancers. Millions of patients could benefit from Epione® treatment worldwide

‍

Quantum Surgical’s flagship product, the Epione® robotic platform is dedicated to the curative treatment of cancers. Epione® allows physicians to treat tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.

Available in Europe and the United States, the Epione® robot has already been used to treat more than 150 patients with liver or kidney cancer.

The extension of the Food and Drug Administration (FDA) authorization allows the commercial sale and use of theEpione® robot in the United States to treat cancers of the entire abdomen. The abdomen is the space between the thorax and the pelvis, and includes in particular the following organs: liver, kidneys and adrenal glands, pancreas.

"We are very pleased to receive the FDA clearance. This decision allows physicians to now treat all abdominal tumors at an early stage and will accelerate the implementation of our innovative Epione® robotics solution in the United States. And ultimately, enable more patients to benefit from innovative and less invasive treatments" says Bertin Nahum, president and co-founder ofQuantum Surgical.

This authorization is supported by clinical data from the Gustave Roussy Cancer Center.

[1] Source: Global Cancer Observatory

Montpellier, France, April 18^th, 2023 - Quantum Surgical announces the ongoing clinical trial for the treatment of lung metastases assisted by the Epione® robot. The study is coordinated by Professor Thierry de Baère, Head of the Therapeutic Imaging Department at Gustave Roussy (Villejuif, France), ranked world's third best cancer hospital in 2023¹. This study will evaluate the clinical performance and safety of the Epione® device for the treatment of these tumors.

Epione® is a robotic platform capable of assisting interventional radiologists in planning and performing minimally invasive procedures for the percutaneous ablation of tumors in the abdomen. Available in France and the United States, the Epione® robot has already been used in procedures on more than 150 patients with liver or kidney cancer. With this study, Quantum Surgical aims to obtain an extension of its marketing authorizations in Europe and the United States with an indication extended to the treatment of lung tumors.

With more than 2 million new cases worldwide in 2020, including approximately 500,000 in Europe, lung cancer is the leading cause of death for cancer patients (18%)².

"This study sets a new milestone in the development of Quantum Surgical, and I am proud that it is being done in collaboration with Gustave Roussy, whose teams see the full potential of our technology. This is another step towards the dissemination of our innovation to other cancer patients” says Bertin Nahum, President and co-founder of Quantum Surgical.

¹ Gustave Roussy dans le TOP 3 mondial des hôpitaux en cancérologie | Gustave Roussy

² Globocan 2020

‍

Montpellier, April 13th 2023 - Quantum Surgical, the Medical Robotic company dedicated to the curative and early treatment of cancers, has appointed Robert Thompson and Joseph de Vivo and on its Board of Directors as Independent Board Members.

Robert Thompson (Bob) is an accomplished marketing and business development leader and brings Quantum Surgical his experience in product development and commercialization in the medtech industry. He previously served as President-Ultrasound Siemens Healthineers, senior leadership positions at GE Healthcare and medical device start-ups.

“I am excited to join such a talented and visionary team. The innovative solutions developed by Quantum Surgical have the potential to  transform cancer treatments by bringing a new standard of minimally invasive care  of cancer patients worldwide” says Robert Thompson.

 Joseph de Vivo brings over 30 years of experience in medical device, robotics and digital health industries. He was most recently Executive Chairman of Caption Health, President of Hospitals and Health Systems for Teladoc Health and CEO of In Touch Health. He previously served as CEO of Angiodynamics and President of Smith & Nephew Orthopedics. Mr De Vivo currently serves as the Treasurer of the American Telemedicine Association and on the Board of Governors for St Jude Children’s Research Hospital. 

“The arrival of Robert and Joseph, two experienced healthtech leaders among our Board Members is a real opportunity for Quantum Surgical and will directly serve our strategy and our development, particularly in the United States”, said Bertin Nahum, CEO and Co-Founder of Quantum Surgical.

‍

Montpellier, France November 16^th, 2022 - Civil Hospitals of Lyon, France (HCL ) have aquired Epione, the robotic platform developed by Quantum Surgical (QS) that is designed to enable minimally invasive ablations of tumors in the abdomen. This partnership between HCL and QS will allow more patients to benefit from Epione, an innovative platform allowing physicians to plan, target, deliver and confirm ablation treatment in a moresecure and precise manner.  Epione is currently utilized to target liver tumors but will be expanded to the treatment of kidney, lungs and pancreas as the radiologists at CHU Lyon expand their robotic interventional oncology practice.

HCL ranks asthe second largest University hospital in France and represents the second hospital in the world to offer this groundbreaking platform.  The first Epione robot was acquired by Gustave Roussy in January 2022 and the team is approaching their 100^throbotic procedure.

"This new acquisition of Epione is a major step for QS and a full validation of the key benefits that Epione offers.  It is a great honor to have our robotic system acquired by one of the top medical robotic institutions in France.  The most exciting part of this story is that patients will now have a powerful new technology that can offer curative treatments by robotically navigating to destroy tumors while sparing surrounding healthy tissue" says Bertin Nahum, co-founder and CEO of Quantum Surgical.

"Epione® is a unique percutanueous robotic solution […] Currently only few experts radiologists  perform these treatments. Robotics will allow to standardize these treatments and more radiologists will thus be able to perform these cases especially the more complex cases on tumors which currently would not be treated . This will allow us to help and cure more patients" says Pr. Laurent Milot, deputy Head of Medical and interventional imagingDepartment-  CHU  Lyon.

Montpellier, France, October 28, 2022 - Quantum Surgical has been awarded the Prix Galien USA 2022, in the medtech start-up category, for its Epione® robotic platform, dedicated to the curative and early treatment of abdominal cancer and in particular liver cancer.

Considered to be the equivalent of the Nobel Prize in biopharmaceutical research, the Prix Galien highlights unique solutions and individuals who have influenced healthcare through innovation. Each year, the award recognises tomorrow's medical excellence in all areas of healthcare: drugs, medical devices and e-health.  

The Prix Galien USA awards were presented to the winners on the evening of Thursday October 27 in New York at a ceremony at the Museum of Natural History.

"This award is an honor, and a recognition of the immense work Quantum Surgical has accomplished since 2017 without ever deviating from our mission: to provide access to minimally invasive treatments to as many cancer patients as possible. In five years, we have developed a robotic platform that is unique in the world, forged numerous scientific and commercial partnerships, and received support from international funds including Ally Bridge Group and the EIB. We have been able to deploy a new solution for curative and early treatment of abdominal cancers in Europe, the United States and China, alongside the most eminent interventional radiologists. I would like to pay tribute to them: they play an essential role in enabling cancer patients to benefit from innovative, better targeted and less aggressive treatments," says Bertin Nahum, co-founder and CEO of Quantum Surgical.

Thanks to the scientific partnerships developed by Quantum Surgical with the Montpellier University Hospital and the Gustave Roussy Institute in Villejuif, almost 100 patients with abdominal cancer have been treated with Epione® to date. Quantum Surgical plans to extend the indications of its technology to other cancers and to add decision support functions based on artificial intelligence algorithms. This is a public health issue, as the number of liver cancers in the world is expected to increase by 55% by 2040, as a study in theJ ournal of Hepatology recently pointed out.

Montpellier, France, October 4, 2022 – Quantum Surgical, a French medical robotics company and the creator of Epione®, a robotic platform for the percutaneous ablation of cancerous tumors, officially inaugurated its new headquarters on Monday, October 3, 2022 in Montpellier.

Bertin Nahum, President and Co-founder of Quantum Surgical, together with his partners, unveiled the new “Quantum Surgical Campus” yesterday in the presence of Michaël Delafosse, Mayor of Montpellier and President of Montpellier Méditerranée Métropole.

“Our campus is now fully aligned with our industrial growth and the pace of our business development: 2,400 m², including 670 m² exclusively dedicated to the production line of our Epione® robot, and 950 m² for housing our research and development activities. We are proud to operate in a space that brings together cutting-edge technology, industrialization, and excellence in innovative healthcare,” says Bertin Nahum, President and Founder of Quantum Surgical.

This new milestone, which also marked the celebration of Quantum Surgical’s fifth anniversary, reflects the scale-up the company has achieved in recent months. Quantum Surgical continues its expansion in France, Europe, the United States through a subsidiary, and in China through a joint venture. The company now has over 100 employees.

Thanks to the scientific partnerships developed by Quantum Surgical — notably with Montpellier University Hospital (CHU) and the Gustave Roussy Institute in Villejuif — more than 60 patients with abdominal cancers have already benefited from treatment using Epione®.

Montpellier, July 25, 2022 - Quantum Surgical is proud to be recognized as one of the #TopTechTomorrow2022 winners by KPMG, a ranking that highlights the champions of Tech in France and future European giants of tomorrow!

This award is hand selected by a panel of experts from the financial community, from a selection of more than 1000 innovative companies and based on a quantitative and qualitative multi-criteria analysis, Quantum Surgical listed among the 85 most promising French Tech companies of this 4th edition of the barometer published by KPMG!

The list of winners is available here : Top Tech Tomorrow 2022 – KPMG France (home.kpmg)

‍

Montpellier, France, March 22, 2022 – Quantum Surgical, an innovative medical robotics company, announced today the US Food and Drug Administration (FDA) 510(k) clearance for Epione®, a new category of interventional oncology robotics dedicated to minimally invasive liver cancer treatment.

"This clearance enables interventional oncologists to access state-of-the-art technology that has the potential to improve clinical outcomes and patient’s lives. We believe that the clinical adoption of innovative robotic solutions like Epione® will be a significant step toward allowing more patients to benefit from minimally invasive therapies in cancer treatment," said Bertin Nahum, President and Co-Founder of Quantum Surgical.

Epione® is a unique robotic-assisted technology designed to plan, target, deliver and confirm tumor ablation. Epione® enables clinicians to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment in which a needle is inserted through the skin to the tumor to destroy it.

“It is tremendous to see Epione® now available in the USA as I believe technology like this will have a meaningful impact in the Interventional Oncology space. Percutaneous tumor ablation is a proven therapy that is underutilized today, and Epione® will allow expansion of this minimally invasive treatment to more patients battling liver cancer,” said Nishita Kothary, Professor of Radiology at Stanford University Medical Center.

The FDA 510(k) clearance permits the commercial sale and the use of the Epione® interventional oncology robot in the United States to facilitate treatment of early-stage liver disease, a leading cause of cancer death. More than 3 million people are diagnosed with liver disease each year throughout the world. The company plans to extend indications for the Epione® platform to other organs and is developing artificial intelligence-based decision-support features.

“Epione® introduces an exciting new era by expanding technical ability and safety in the diagnosis and treatment of lesions anywhere in the liver,” added Prof. Steven Colquhoun, Liver Transplant Surgeon, who specializes in robotic surgery at Cedars-Sinai Medical Center.

This clearance is supported by clinical data from Prof. Thierry de Baere (Gustave Roussy Cancer Center, France) and Prof. Boris Guiu (Montpellier University Hospital, France), whose teams used the Epione® system to treat primary and secondary liver tumors.

‍

Montpellier, France, January 11, 2022 – The internationally renowned Gustave Roussy cancer center has become the first hospital globally to offer minimally invasive robotic procedures with the Epione® device, the medical robot developed by Quantum Surgical for liver cancer treatment.

This first contract between Quantum Surgical, an innovative company developing medical robots, and Gustave Roussy (Villejuif, France), Europe's leading cancer center, aims to enable more patients to benefit from Epione® for the minimally invasive treatment of abdominal tumors. This technique involves inserting a needle through the skin to destroy tumors.

Professor Thierry De Baere, head of the Therapeutic Imaging Department at Gustave Roussy, and his team will be the first in the world to use the Epione® robot in their routine clinical practice. Dr. De Baere is a world renowned expert in Interventional Oncology and he previously participated in the first clinical trial of Epione®, which successfully treated liver cancer robotically.

"Gustave Roussy is one of the world's leading cancer centers and we are proud to have them be Quantum Surgical's first customer of the Epione® robot. This installation will allow us to take a major step in cancer treatment by offering patients an innovative and minimally invasive treatment for liver tumors. Gustave Roussy is the ideal institution to partner with to showcase the potential of Epione® to help physicians perform safe and effective percutaneous tumor ablation in the abdomen and accelerate the clinical adoption of our medical robot," said Bertin Nahum, President and Co-Founder of Quantum Surgical.

"We look forward to evaluating new possibilities for minimally invasive treatment of small primary or secondary liver tumors for Gustave Roussy patients," said Professor Thierry De Baere, Head of the Therapeutic Imaging Department at Gustave Roussy and a member of Quantum Surgical's scientific advisory board.

Montpellier, France, Oct 19th, 2021 - Quantum Surgical, an innovative medical robotic company, announced today that it has secured €40 million (US$48 million) of financing. Led by existing key investor Ally Bridge Group (“ABG”) with an investment of €20 million (US$24 million), this round also includes funding from the European Investment Bank, Bpifrance, and Caisse d'Epargne Languedoc Roussillon. This brings the total amount of funds completed by Quantum Surgical to €50 million since its inception.

Following CE mark approval announced in September, this funding will support company’s operations dedicated to the commercial launch of Epione®, a medical robot designed to assist physicians in performing safer and more efficient percutaneous tumor ablations in the abdomen. Epione® aims to allow more patients to benefit from minimally invasive liver cancer treatment, a technique consisting of inserting a needle percutaneously to burn a tumor.

"We are delighted to have closed this round of financing and honored by the strong, continued support of our key long-term investor Ally Bridge Group all the way since the days of our previous company Medtech SA just before its acquisition by Zimmer Biomet in 2016. These additional funds will support the company to accelerate the clinical adoption of Epione®, our medical robot for liver cancer treatment," said Bertin NAHUM, CEO, and co-founder of Quantum Surgical.

“As an early investor of Quantum Surgical, ABG is proud to continue to support the company’s impressive achievement throughout the Covid-19 pandemic, evidenced by its recent CE mark approval,” said Frank Yu, Founder, CEO and CIO at Ally Bridge Group. “We expect to see significant milestones to be achieved by Quantum in the near term that will allow Epione® to treat more liver cancer patients sooner and better than the current standard of care.”

“The EIB is pleased to contribute to the development of Quantum Surgical and its innovative technology to improve the treatment of liver cancer. Against the continued Covid-19 challenges, this €15 million funding, with the backing of the Pan European Guarantee Fund (EGF), demonstrates Europe's focus on supporting innovation and promising technologies in the field of healthcare, an area that is essential for people's well-being", said Ambroise Fayolle, vice-president of the European Investment Bank.

Montpellier, France, September 7, 2021 - Quantum Surgical, an innovative medical robot-ics company, announces that it has recently obtained CE mark approval for Epione®, its robot designed for minimally invasive treatment of abdominal tumors. This authorization allows the commercial launch of Epione® on the European market.

Epione® is a robotic solution developed to help physicians perform safer and more effec-tive percutaneous ablations in the abdomen, a minimally invasive treatment in which a needle is inserted through the skin to the tumor to remove it. Epione® ensures reliability and accuracy, two key factors to improve current practice and reduce variability. Epione®, assists practitioners in managing patients, from preoperative planning to the end of the procedure.

The CE mark follows the successful treatment of 21 patients with the Epione® robot in a multi-center clinical study completed earlier this year.

"This is a major milestone for Quantum Surgical, as the CE mark approval is the starting point towards the commercialization of the robot. This clearance will allow many more patients to benefit from Epione® as there is a significant need for minimally invasive ther-apies in cancer treatment," declares Bertin NAHUM, CEO, and co-founder of Quantum Sur-gical.

‍

Montpellier, France, May 17, 2021 - QuantumSurgical, an innovative medical robotic company, announced today the expansionof its Scientific Advisory Board (SAB) with the appointment of Pr. Thierry de Baere, Head of the Therapeutic Imaging Department atGustave Roussy, first cancer center in Europe.

The Quantum Surgical SAB is amulti-disciplinary board composed of international experts in the field ofimage-guided interventional oncology:

• Professor Steven D. Colquhoun (US), Liver transplant surgeon,specialized in robotic surgery at Cedars-Sinai Medical Center (Los Angeles, CA).

• Professor Thierry De Baere (FR), Head of theTherapeutic Imaging Department at Gustave Roussy Cancer Center (Villejuif).

• Professor Boris Guiu (FR), InterventionalRadiologist, Head of St Eloi Department of Diagnostic and InterventionalRadiology at Montpellier University Hospital (Montpellier).

• Professor Nishita Kothary (US), InterventionalRadiologist at Stanford University Medical Center (Stanford, CA).

• Professor David C. Madoff (US), InterventionalRadiologist at Yale New Haven Hospital (New Haven, CT).

Professor Luigi Solbiati (IT),InterventionalRadiologist, pioneer of percutaneous liver ablation techniques, Professor ofRadiology at Humanitas University (Rozzano - Milan), joins Professor GuyVallancien (FR), urology surgeon, and pioneer of laparoscopic and roboticsurgery, as honorary member of this Scientific Advisory Board.

Quantum Surgical is actively preparing to launch inEurope Epione®, a unique robotic platform designed to assist the physician inperforming safer and more efficient percutaneous thermal ablations in the liver(a minimally invasive treatment in which a needle is inserted through the skinto the malignancies to burn them).

“We are honored anddelighted to expand our SAB with the appointment of Professor Thierry de Baere,who took part in our first clinical study in which 21 patients were successfullytreated in France,” declaresBertin Nahum, CEO, and co-founder of Quantum Surgical. “We will continue to benefitfrom precious advice provided by these internationally renowned physicians todevelop clinical adoption in the European and American markets.”

Montpellier, France, Tuesday February 16, 2021 - Quantum Surgical, an innovative surgical robotic company, announced today that it has successfully completed a first multicenter clinical study with its Epione® medical robot dedicated to minimally invasive liver cancer treatment.

The Epione® platform is designed to assist the physician in performing safer and more efficient percutaneous ablations in the liver (a minimally invasive treatment in which a needle is inserted through the skin to the lesion to burn it).

Professor Boris GUIU, Professor Thierry DE BAERE and their respective teams successfully treated 21 patients with the assistance of Epione® in this clinical trial carried out at Montpellier University Hospital (Montpellier, France) and at Gustave Roussy Cancer Center (Villejuif, France).

During these interventions, 24 liver tumors, whether they were primary (from the liver) or metastatic (from another organ) were successfully targeted and destroyed and furthermore the postoperative exams revealed no complications.

"The 21 patients treated were able to benefit from an innovative robotic guidance platform assisting in CT-guided percutaneous tumor destruction treatments. These patients were efficiently treated, pending definitive results which seem encouraging” explains Professor Boris GUIU, Interventional Radiologist, Head of the Department of Diagnostic and Interventional Radiology of Saint Eloi (Montpellier University Hospital) and Professor Thierry DE BAERE, Head of the Therapeutic Imaging Department at Gustave Roussy.

"The completion of this first clinical trial is a key milestone to Epione’s® premarket approval” announces Bertin NAHUM, President and Founder of Quantum Surgical.

‍

Montpellier, France, November 10, 2020 – On November 9, 2020 Professor Thierry de Baere and his team at Gustave Roussy Hospital (Therapeutic Imaging Department) successfully treated a patient with liver tumor on an outpatient basis using Quantum Surgical’s Epione® medical robot.

“Minimally invasive” interventions, which involves, among other factors, smaller incisions and adapted anesthesia methods compared to the so-called “conventional” procedures, reduces postoperative risks and patients, in turn, see a shorter recovery time. Outpatient surgery allows a person to return home on the same day that a surgical procedure is performed.

The development of outpatient interventions is a real step forward in terms of quality of care for patients. Unfortunately, this procedure is still not sufficiently developed in the World even though it could be convenient for many patients.

The Epione® platform aims to increase the number of patients who can benefit from percutaneous ablation of liver tumors (a minimally invasive treatment in which a needle is inserted through the skin to the lesion to burn it).

The first ambulatory patient treated with the assistance of Epione® is a key milestone for Quantum Surgical, as it illustrates the potential of its technology to contribute to value-based medicine through the development of outpatient care.

“It is always an immense pleasure and pride to work with a partner recognized as one of the best cancer hospitals in the world and to contribute with our technology to the development of outpatient care” explains Bertin Nahum, President, and co-founder of Quantum Surgical.

Montpellier, France, Tuesday, September 22, 2020 – Quantum Surgical, an innovative company developing a robotic platform for the early treatment of liver cancer, announces that it has been awarded a €200,000 grant from the Occitanie Region.

This investment grant, awarded as part of the regional support plan for businesses known as the “Pass Rebond Occitanie,” is intended to support company development projects in anticipation of economic recovery following the Covid-19 health crisis.

The funding will enable the company to implement an Enterprise Resource Planning (ERP) system, which is essential for the upcoming market launch of its first product aimed at treating liver tumor lesions.

“We are extremely grateful for the support provided to businesses by the Occitanie Region, especially during this health crisis. This grant will allow us to continue developing our robotic platform, which is scheduled to be launched in 2021,” said Christophe Sibillin, Chief Financial Officer of Quantum Surgical.

Montpellier, France, July 9, 2020 - Professor Thierry de Baere and his team from the therapeutic imaging department of Gustave Roussy Hospital successfully treated, on July 7, 2020, a patient with liver metastases using Quantum Surgical's medical robot.

This successful intervention opens new perspectives for the treatment of patients with hepatic metastases (caused by cancers other than liver cancer) with the guidance of Quantum Surgical's medical robot.

Indeed, while liver cancer affects more than 800,000 new patients each year worldwide (1), liver metastases affect three times as many patients (2.4 million new patients each year worldwide (1)).

Quantum Surgical's device; a combination of powerful software and robotic platform, is designed to assist the physician in performing safer, more efficient and less invasive oncology treatments.

It is a "made in France" robotic platform, developed, designed and produced in Montpellier by Quantum Surgical, an innovative company co-founded and directed by Bertin Nahum, an experienced entrepreneur in medical robotics.

"Once its safety and performance on both primary liver tumors and liver metastases have been confirmed in the clinical trial, the device may prove to be a valuable aid in increasing the accuracy and widely disseminate less invasive percutaneous tumor destruction treatments for patients," explains Professor Thierry De Baere, Head of the therapeutic Imaging Department at Gustave Roussy Hospital.

"It is a pleasure and an honor to work with a French Top-Tier Hospital to expand our indications and allow more and more patients to benefit from robotic assistance for minimally invasive procedures," announces Bertin Nahum, President and Founder of Quantum Surgical.

(1) Globocan, 2018

Montpellier, France, July 1, 2020 - Quantum Surgical, an innovative company developing a Surgical Robot for liver cancer treatment, announces today that the company has obtained a €4.8 million State Guaranteed Loan (PGE).

This loan, granted by Crédit Agricole, Dupuy de Parseval Bank, and the French Public Bank for Investment (BPI) as part of the measures to support the economy, will enable the company to pursue the development of its product which is expected to be commercialized in 2021 in Europe.

“Thanks to our partner banks and the BPI who quickly mobilized to grant us this loan, and thus confirm their confidence in our project, we will be able to continue our development activities aimed at obtaining Regulatory authorizations of our robotic platform needed before its commercialization” announces Christophe Sibillin, Chief Financial Officer at Quantum Surgical.

Discover the power of Robotics in Image Guided Ablation during our upcoming webinar, featuring a live Q&A. Get your questions answered by experts from around the world. Don't miss this insightful session brought to you by Spectrum Cancer and Quantum Surgical.

‍

Topics include:

• Benefits and challenges of robotics during ablation procedures
• Learning curves
• How to approach administration about adopting robotics
• Case presentations
• And live Q&A

Join us for this virtual event with live Q&A.

Limited spots. 

REGISTER NOW!

Join Quantum Surgical and leading experts from Miami Cardiac and Vascular Institute, Miami Cancer Institute, a part of Baptist Health South Florida for a webinar on robotic-assisted ablation for abdominal tumors. Learn how cutting-edge robotic technology is transforming minimally invasive treatments and building a pioneering interventional oncology program in the U.S.

The guest speakers include Govindarajan Narayanan, MD, Chief of Interventional Oncology, Constantino Santiago Peña, MD; Ripal Gandhi, MD; Gina Landinez, MD; and Daniela Garcia, MD, Fellow.

Interventional oncology continues to play a pivotal role in addressing the increasing demands of the growing oncology market. With more patients being diagnosed earlier, the need for safe, efficient, and minimally invasive treatment options has never been greater. As hospitals seek cost-effective solutions, the demand for innovative cancer treatments rises steadily. Robotic-assisted technologies like Epione^® are standardizing care delivery, offering enhanced precision, efficiency, and patient outcomes in treating abdominal tumors through percutaneous ablation.

Click here to register for our webinar featuring the first hospital in the US to adopt robotic-assisted technology and hear how it’s changed their approach in interventional cancer care.

‍